Compare UTZ & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UTZ | NBTX |
|---|---|---|
| Founded | 2018 | 2003 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 912.7M | 1.0B |
| IPO Year | N/A | 2020 |
| Metric | UTZ | NBTX |
|---|---|---|
| Price | $9.38 | $24.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | $14.00 | ★ $26.00 |
| AVG Volume (30 Days) | ★ 1.7M | 22.3K |
| Earning Date | 02-12-2026 | 04-01-2026 |
| Dividend Yield | ★ 2.75% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $1,437,681,000.00 | $11,930,711.00 |
| Revenue This Year | $3.17 | N/A |
| Revenue Next Year | $2.96 | $145.24 |
| P/E Ratio | $144.21 | ★ N/A |
| Revenue Growth | ★ 1.22 | N/A |
| 52 Week Low | $8.72 | $2.95 |
| 52 Week High | $14.67 | $30.35 |
| Indicator | UTZ | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 31.57 | 60.40 |
| Support Level | $10.71 | $22.76 |
| Resistance Level | $11.30 | $25.55 |
| Average True Range (ATR) | 0.47 | 1.13 |
| MACD | -0.15 | 0.40 |
| Stochastic Oscillator | 5.80 | 72.91 |
Utz Brands Inc is a manufacturer of branded salty snacks. It produces a broad offering of salty snacks, including potato chips, tortilla chips, pretzels, cheese snacks, pork skins, pub/party mixes, and other snacks. Its iconic portfolio of authentic, craft, and better-for-you (BFY) brands, which includes Utz, Zapp's, On The Border, Golden Flake, and Boulder Canyon, among others, enjoys household penetration in the United States, where its products can be found in approximately half of U.S. household. The company operates in eight manufacturing facilities with a broad range of capabilities, and its products are distributed nationally to grocery, mass, club, convenience, drug, e-commerce and other retailers through direct shipments, distributors, and approximately 2,500 DSD routes.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.